Grey Scores With GSK, Bausch & Lomb

Grey has won two consumer healthcare accounts, adding global advertising duties for GlaxoSmithKline’s Panadol pain-relief brand and Bausch & Lomb’s pharmaceutical business unit.
Billings for Panadol are $100 million, while the Bausch & Lomb assignment is worth $50 million, sources said.

The GSK business had primarily been at Grey’s WPP corporate sibling Ogilvy & Mather, which handled the chores in regions like the U.K. and South America. Grey already worked on the brand in several Asian markets. (GSK has been a Grey client since 1955, with the agency handling products like Aquafresh, Breathe Right, FiberChoice, Polident, Sensodyne and Tums.)
Bausch & Lomb’s pharmaceutical unit previously used agencies like Interpublic Group’s TM Advertising and Havas’ Euro RSCG for project work. Partners + Napier and IPG’s TM and DraftFcb remain primary agencies for Bausch + Lomb’s vision care business unit.
“The global consolidation of Panadol represents a tremendous vote of confidence in our longtime partnership with GSK,” said Jim Heekin, chairman and CEO of Grey Group, in a statement. “We are delighted to welcome Bausch & Lomb, one of the world’s most iconic brands, to our client roster.”

See also: “$700 MIl. GSK Media in Play”